Waters Corporation demonstrated solid financial performance through 2025 despite modest operating income headwinds, underpinned by its integrated chromatography and mass spectrometry systems. The 2026 acquisition of Becton Dickinson’s Biosciences and Diagnostic Solutions businesses broadens Waters’ technological scope and customer base, prompting a reorganization from two to four business segments to better capture diversified end-market opportunities. Operating cash flows remain robust, supporting measured buyback activity amid increased equity from acquisition-related transactions. Key risks include integration complexities, fluctuations in customer capital spending—particularly from pharmaceutical clients—and intense innovation competition. Monitoring upcoming segment disclosures and consumables revenue dynamics will be crucial as Waters seeks to leverage its expanded footprint for sustained growth.